DiagnosTear Technologies (X8F) Stock Overview

An ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. More details

X8F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Has not reported any financial data

Shares are highly illiquid

Does not have a meaningful market cap (€33M)

X8F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

DiagnosTear Technologies Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for DiagnosTear Technologies
Historical stock prices
Current Share Price	CA$0.29
52 Week High	CA$0.30
52 Week Low	CA$0.18
Beta	0
1 Month Change	16.67%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	51.29%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	X8F	DE Medical Equipment	DE Market
7D	34.1%	2.4%	0.1%
1Y	n/a	-0.9%	12.1%

Return vs Industry: Insufficient data to determine how X8F performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how X8F performed against the German Market.

Price Volatility

Is X8F's price volatile compared to industry and market?
X8F volatility
X8F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	12.3%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: X8F's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine X8F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2023	n/a	Shimon Gross	diagnostear.com

DiagnosTear Technologies Inc., an ophthalmic company, engages in developing and commercializing disruptive diagnostic solutions for eye diseases. It develops TeaRx Dry Eye, a CE-IVD approved test based on the TeaRx platform intended for the identification and monitoring of Dry Eye Syndrome (TeaR DES); TeaRx Red Eye for differential assessment of adenoviral conjunctivitis, herpetic keratitis, and allergic conjunctivitis; and TeaRx Tear Collector, a proprietary microfluidic tear collector that allows non-invasive collection of 1 microliter of tear fluid and dilution in the assay buffer for downstream analytical testing. DiagnosTear Technologies Inc. was formerly known as Oceanview Technologies Inc. and changed its name to DiagnosTear Technologies Inc. The company was incorporated in 2023 and is headquartered in Rehovot, Israel.

DiagnosTear Technologies Inc. Fundamentals Summary

How do DiagnosTear Technologies's earnings and revenue compare to its market cap?
X8F fundamental statistics
Market cap	€19.96m
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is X8F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
X8F income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did X8F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/27 21:01
End of Day Share Price	2025/10/24 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DiagnosTear Technologies Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.